Alzheimer’s disease treatment market size was valued at US$ 6.1 Billion in 2020 and is expected to grow US$ 9.05 Billion by 2027 at a CAGR of 5.8% during the forecast period. Alzheimer's disease is a neurodegenerative disorder that attacks the brain's nerve cells, or neurons, leading to cell death and degeneration. The most common symptoms of Alzheimer's disease are memory loss, incognition, disorientation, behavioural changes, personality changes, and trouble in speaking and writing. Alzheimer's disease (AD) mainly occurs in adults with aging mid-sixties, which leads to 60% to 70% of cases of dementia. The major causes of Alzheimer's disease are genetic disorders and the disease process associated with plaques and tangles in the brain. The diagnostic test for Alzheimer's disease includes cognitive testing with medical imaging and blood tests.  Alzheimer’s disease risks can be overcome by mental and physical exercise and avoiding obesity. Alzheimer’s disease treatment market is expected to grow at a significant CAGR due to an increase in the prevalence of Alzheimer’s disease. According to World Health Organisation, escalation of the geriatric population leads to an increase in Alzheimer's disease cases, which in turn affect the market positively over the forecast period. Apart from this, increase in healthcare spending and R&D investments in the global Alzheimer’s research, expiration of patents, and entry of new generics into the market expected to fuel the growth of the market. Similarly, the discovery of new disease-modifying drugs, and presence of vast last-stage pipeline drugs expected to boost the market over the forecast period. However, the limited number of treatment options for Alzheimer’s disease in the market, challenges in precise diagnosis and even detection of Alzheimer's disease, and lack of funding from government in developing economies for research might hamper the growth of the market over the forecast period. Moreover, the high degree of research failure and uncertainty within the research and development of drugs might hinder the growth of the Alzheimer’s disease treatment market.  

Key Development:

  On May 09, 2022, EISAI completes rolling submission to the U.S. FDA  for Biologics Licence Application (BLA) of LECANEMAB fro early ALZHEIMER’S disease approval pathway for the investigational anti-amyloid beta (A?) protofibril antibody lecanemab (BAN2401) for the treatment of mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) and mild AD (collectively known as early AD) with confirmed presence of amyloid pathology in the brain. EISAI has requested priority review for the same. Dependent upon the results of the Clarity AD clinical trial, Eisai may submit for full approval of lecanemab to the FDA during fiscal year 2022.   On July 08, 2021, Biogen and Eisai Co., Ltd. announced the U.S. Food and Drug Administration (FDA) has approved an updated label for ADUHELMâ„¢ (aducanumab-avwa) injection 100 mg/mL solution.